T cells are supposed to be relentless. These white blood cells patrol the body, identify threats, and destroy them. But inside solid tumors, something goes wrong. The tumor environment is hostile by design, flooding immune cells with suppressive signals and starving them of resources. Over time, T cells exposed to cancer lose their capacity to fight, entering a state researchers call exhaustion. They’re still there, still present, but functionally spent. Reversing that exhaustion has been one of the central challenges in cancer immunotherapy, particularly for tumors growing within organs. In these organs, existing therapies have largely failed. Now, engineers at the University of Pennsylvania have built a nanoparticle that attacks the problem from two directions at once. As a result, the research team describes the results in animal models as striking. The new particles, described in Nature Nanotechnology, eliminate established colon tumors in mice, protect against recurrence, and even cause distant, untreated tumors to shrink. While the work remains preclinical, the underlying approach may offer a path toward immunotherapy that works broadly across solid tumor …